🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs
5,427

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Page 49 of 114

  1. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  2. LHRHa

    Janssen Cilag International NV

    Prostatic Neoplasms

    phase 3 small molecule active

    1 trial

  3. LI

    Teva Pharma GmbH

    Squamous Cell Carcinoma of the Oral Cavity

    phase 3 mab completed

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  5. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. LIBTAYO 350 mg concentrate for solution for infusion., matching Placebo with R2810

    Lacuna Pharma Pty Ltd

    Cutaneous Squamous Cell Carcinoma (CSCC)

    phase 3 small molecule active

    1 trial

  8. LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 µg

    Disc Medicine

    Hypothyroidism Triiodothyronine Quality of Life Persistant complaints

    phase 3 small molecule active

    1 trial

  9. LIPO-202

    Evofem Biosciences

    Central Abdominal Bulging

    phase 3 small molecule terminated

    2 trials

  10. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  11. LMT (atorvastatin, simvastatin, or rosuvastatin)

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  12. LNP023

    Novartis Pharmaceuticals

    Primary IgA Nephropathy

    phase 3 small molecule active

    1 trial

  13. LOMUSTINE

    Ningbo Cancer Hospital

    Glioblastoma

    phase 3 small molecule active

    1 trial

  14. LOMUSTINE, 4-L-[131I]iodo-phenylalanine, LOMUSTINE

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 3 small molecule active

    1 trial

  15. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  16. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi-aventis Healthcare Pty Ltd

    Pruritus

    phase 3 small molecule active

    1 trial

  17. LORLATINIB

    Pfizer Australia Pty Ltd

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  18. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Australia Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  19. LOU064

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  20. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  21. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  22. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  23. LOU064, Placebo to Remibrutinib (LOU064) XX mg film-coated tablet, -, -

    Novartis Pharmaceuticals

    Chronic Inducible Urticaria (CINDU)

    phase 3 small molecule active

    1 trial

  24. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  25. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  26. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  27. LPA1 antagonist, LPA1 antagonist, Placebo for BMS-986278

    Bristol-Myers Squibb Australia Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 3 small molecule active

    1 trial

  28. LPA1 antagonist, Placebo for BMS-986278, LPA1 antagonist

    Bristol-Myers Squibb Australia Pty Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  29. LUM

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial

  30. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  31. LY2127399

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  32. LY2127399

    Eli Lilly and Company

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  33. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  34. LY2216684

    Eli Lilly and Company

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  35. LY3819253

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  36. Lactobacillus plantarum

    United Therapeutics Europe Ltd

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  37. Lactobacillus plantarum IS-10506

    United Therapeutics Europe Ltd

    Constipation - Functional

    phase 3 small molecule completed

    1 trial

  38. Lactose Placebo

    United Therapeutics Europe Ltd

    Elbow Fracture

    phase 3 small molecule completed

    1 trial

  39. Lactose monohydrate, Melatonine Tiofarma 5 mg tabletten

    Disc Medicine

    Chronic low back pain

    phase 3 small molecule active

    1 trial

  40. Lanadelumab

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    2 trials

  41. Lanadelumab

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  42. Lanadelumab

    Takeda

    Angioedema

    phase 3 small molecule completed

    2 trials

  43. Lansoprazole

    Takeda

    Stomach Ulcer

    phase 3 small molecule completed

    2 trials

  44. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  45. Lansoprazole microgranules suspension

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  46. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  47. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Ozempic 2 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  48. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.